Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.
Acknowledgment of Commercial Support
This educational activity is supported by an educational grant from GlaxoSmithKline plc.
Leveraging Phenotypic Data in Severe Asthma Control: Are You Individualizing Your Patient's Treatment?
Release Date: July 15, 2020
Expiration Date: July 15, 2021
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in asthma treatment to provide insight on how to manage patients with severe, uncontrolled asthma. Asthma is a chronic inflammatory disease with distinct phenotypes that originates from a complex interplay between genetic and environmental factors. Exploring an individual’s asthma phenotype is becoming increasingly important to help select the optimal targeted therapy that aims at controlling symptoms and reducing the risk of future exacerbations.
This educational activity is an archive of a live virtual symposium held on June 24, 2020.
Acknowledgment of Commercial Support
This educational activity is supported by an educational grant from GlaxoSmithKline plc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational program is directed toward all pulmonologists, allergists, and primary care physicians.
Nurses, nurse practitioners, physician assistants, and other healthcare providers who treat patients with asthma may also participate.
Learning Objectives
Upon successful completion of this educational activity, you should be better prepared to:
- Discuss the role of eosinophils in the spectrum of eosinophilic asthma phenotypes
- Evaluate the efficacy and safety of therapies for patients with eosinophilic asthma
- Develop strategies for shared decision making and asthma action plans with patients affected by eosinophilic asthma
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Faculty

Senior Attending Physician, Collegeville Family Practice
Medical Director, Health Services, Ursinus College
Cofounder, Brookside Family Practice and Pediatrics
Pottstown, PA
Disclosures: Paul P. Doghramji, MD, FAAFP has no relevant financial relationships with commercial interest to disclose.
Professor, Pulmonary and Critical Care Medicine
Director, Mary Parkes Center for Asthma, Allergy & Pulmonary Care
University of Rochester School of Medicine and Dentistry
Rochester, NY
Disclosures: Grant Research Support: GlaxoSmithKline, Sanofi.

Associate Professor of Medicine
Division of Pulmonary Diseases and Critical Care
University of Texas Health Science Center at San Antonio
Medical Director, Respiratory Care
Medical Director, Severe Asthma Program
University of Texas Health
San Antonio, TX
Disclosures: Grant Research Support: AstraZeneca; Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi; Speakers Bureau: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi, Sunovion.
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
Director, The Cohen Family Asthma Institute
National Jewish Health
Denver, CO
Disclosures: Grant Research Support: AstraZeneca, Regeneron Sanofi, Teva; Consultant: AstraZeneca, Equillium, Genentech, Genzyme, GlaxoSmithKline, Novartis, Regeneron, resTORbio , Sanofi.
The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.


.jpg)